ClinicalTrials.gg

Program

azvudine

Also written as “Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)”, “Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)” and “Azvudine tablets(FNC) and Rifampicin Capsules (RIF)”.

Its studies are mostly in COVID-19 · Renal Insufficiency, led by 2 companies.

Furthest: phase 3, since May 8, 202510 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Henan Genuine Biotech81 open or runningphase 1since May 8, 2025May 8, 2025none ahead
Fosun Pharma20 open or runningphase 3since Nov 30, 2022Nov 30, 2022none ahead

Also a collaborator on its studies: henan-sincere-biotech-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 30, 2022First study: phase 3 study in COVID-19New to Fosun PharmaFosun Pharma · NCT05633433 · 1,550 enrolled · Malaysia, Philippines
  2. Jan 10, 2023Phase 2 study in COVID-19Fosun Pharma · NCT05682599 · 300 enrolled · China
  3. May 8, 2025Henan Genuine Biotech's first studies: 8 phase 1 studiesNew to Henan Genuine BiotechHenan Genuine Biotech · NCT06991634, NCT07002281, NCT07002255 and 5 more

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Reverse transcriptase inhibitor; Replicase polyprotein 1ab inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07001501Healthy · China1CompletedHenan Genuine BiotechApr 25, 202215
NCT07001488Healthy · China1CompletedHenan Genuine BiotechMay 1, 202215
NCT07001436Renal Insufficiency · China1RecruitingHenan Genuine BiotechAug 30, 202540
NCT07002281Healthy · China1CompletedHenan Genuine BiotechOct 10, 20246
NCT07002255Healthy · China1CompletedHenan Genuine BiotechMar 22, 202215
NCT07002242Healthy · China1CompletedHenan Genuine BiotechAug 25, 202215
NCT07002229Healthy · China1CompletedHenan Genuine BiotechFeb 23, 202215
NCT06991634Healthy · China1CompletedHenan Genuine BiotechApr 27, 202324
NCT05682599COVID-19 · China2UNKNOWNFosun PharmaApr 15, 2023300
NCT05633433COVID-19 · Malaysia, Philippines3UNKNOWNFosun PharmaJun 15, 20241,550

How it is read

Names in the registry

  • “Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)”, 3 entries
  • “Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)”, 3 entries
  • “Azvudine tablets(FNC) and Rifampicin Capsules (RIF)”, 3 entries
  • “Azvudine tablets”, 2 entries
  • “Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
azvudine (Henan Genuine Biotech): development program | ClinicalTrials.gg